Biogen Advances Diranersen After Tau ASO Data
Biogen presented Phase 2 CELIA data for diranersen, an intrathecally administered antisense oligonucleotide designed to reduce tau protein production by targeting MAPT mRNA in early Alzheimer’s disease. The 60 mg dose slowed decline by…
